Cover Image
市場調查報告書

EpiCast Report:僵直性脊椎炎的流行病學預測

EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 298494
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:僵直性脊椎炎的流行病學預測 EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024
出版日期: 2015年08月01日 內容資訊: 英文 58 Pages
簡介

僵直性脊椎炎為全身性、慢性、進行性的發炎性關節炎,是最常見的風濕性疾病之一。全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本)的僵直性脊椎炎的患病人數,預計基準情形從2014年的106萬7,905人,到2024年增加到127萬9,010人。

本報告以全球主要7個國家關於的僵直性脊椎炎為主題,提供危險因素的概要與全球趨勢、流行病學預測、流行病學報告、疾病趨勢的分析。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球的趨勢
    • 美國
    • EU5個國家
    • 日本
  • 預測手法
    • AS患病診斷利用之資訊來源
    • Nr-axSpA 患病診斷利用之資訊來源
    • AS診斷中HLA-B27血清反應陽性的盛行率計算利用之資訊來源
    • AS患病診斷未利用之資訊來源
    • 預測的前提條件與手法(基準及替代方案)
  • 僵直性脊椎炎的流行病學預測-基準方案
    • 確診的患病人數
    • 確診的患病人數:各年齡
    • 確診的患病人數:性別
    • 確診的盛行率:年齡標準化
    • 確診的Nr-axSpA 患病人數
    • HLA-B27血清反應陽性的盛行率
  • 僵直性脊椎炎的流行病學預測-替代方案
    • 確診的AS患病人數
    • 確診的Nr-axSpA患病人數
  • 討論
    • 流行病學趨勢相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER056-15

Ankylosing spondylitis (AS) - a systemic, chronic, and progressive inflammatory arthritis, is the prototype of a family of related disorders known as seronegative spondyloarthritis (SpA) and one of the most common rheumatic diseases across the globe. AS primarily affects the spine and sacroiliac (SI) joints and progresses into severe inflammation that fuses the spine, leading to permanent painful stiffness of the back. AS that occurs before any structural changes in the spine is referred to as non-radiographic axial spondyloarthritis (nr-axSpA) which is the early stage of AS. Some of non-radiographic axial spondyloarthritis progress to AS and some do not.

GlobalData's epidemiological analysis provides a country-specific forecast for the diagnosed prevalent cases of AS in the 7MM during 2014-2024. GlobalData epidemiologists made sure all the country-specific studies report diagnosed prevalent cases of AS, diagnosed prevalent cases of nr-axSpA, and HLA-B27 seropositivity cases in diagnosed AS cases based on medical chart review by a physician or data extracted from national registries. GlobalData epidemiologists provide a forecast for the diagnosed prevalent cases of AS and nr-axSpA using two different approaches: 1) forecasting the diagnosed prevalent cases of AS and nr-axSpAusing data obtained from peer reviewed journal articles and 2) forecasting the diagnosed prevalent cases of AS and nr-axSpA by applying a trend based on data obtained from primary research to the diagnosed prevalent cases calculated using the base scenario. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

The diagnosed prevalent cases of AS in the 7MM in the base scenario increased from 1,045,903 diagnosed prevalent cases in 2014 to 1,067,905 diagnosed prevalent cases in 2024, with an annual growth rate (AGR) of 0.21%. The forecast in the alternate scenario based on primary research data showed that there will be a substantial increase in the diagnosed prevalent cases of AS in the 7MM from 1,279,010 diagnosed prevalent cases in 2014 to 2,230,825 diagnosed prevalent cases in 2024, at an AGR of 7.44%. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

Scope

  • The Ankylosing Spondylitis EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for ankylosing spondylitis (AS) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of ankylosing spondylitis segmented by sex, age (in ten-year increments beginning at 15 years and ending at =65 years), and diagnosed prevalent cases of non-radiographic axial spondyloarthritis, and diagnosed prevalent cases of AS segmented by HLA-B27 seropositivity status in these markets.
  • The ankylosing spondylitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Ankylosing Spondylitis EpiCast series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global ankylosing spondylitis market.
  • Quantify patient populations in the global ankylosing spondylitis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for ankylosing spondylitis therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used for Diagnosed Prevalence of AS
    • 3.4.2. Sources used for Diagnosed Prevalence of Nr-axSpA
    • 3.4.3. Sources Used for the Prevalence of HLA-B27 Seropositivity in Diagnosed AS
    • 3.4.4. Sources Not Used
    • 3.4.5. Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario
    • 3.4.6. Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA - Base Scenario
    • 3.4.7. Forecast Assumptions and Methods, HLA-B27 Seropositivity in Diagnosed AS
    • 3.4.8. Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Alternative Scenario
    • 3.4.9. Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSp - Alternative Scenario
  • 3.5. Epidemiological Forecast for AS (2014-2024) - Base Scenario
    • 3.5.1. Diagnosed Prevalent Cases of AS
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of AS
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of AS
    • 3.5.4. Age-Standardized Diagnosed Prevalence of AS
    • 3.5.5. Diagnosed Prevalent Cases of Nr-axSpA
    • 3.5.6. Prevalent Cases of HLA-B27 Seropositivity in Diagnosed AS Cases
  • 3.6. Epidemiological Forecast for AS (2014-2024) - Alternative Scenario
    • 3.6.1. Diagnosed Prevalent Cases of AS
    • 3.6.2. Diagnosed Prevalent Cases of Nr-axSpA
  • 3.7. Discussion
    • 3.7.1. Epidemiological Forecast Insight
    • 3.7.2. Limitations of the Analysis
    • 3.7.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Diagnostic Criterion for AS and Nr-axSpA
  • Table 2: Risk Factors and Comorbidities for AS
  • Table 3: Summary of the Global Reported Prevalence of AS
  • Table 4: Incidence of AS, Cases per 100,000 Population, 1935-1973, Rochester, Minnesota, US
  • Table 5: Annual Incidence of AS, Cases per 100,000 Population, 1980-1990, Finland
  • Table 6: 7MM, Sources of Diagnosed Prevalence Data for AS used in the Epidemiology Forecast
  • Table 7: 7MM, Sources of Diagnosed Prevalence Data for Nr-axSpA used in the Epidemiology Forecast
  • Table 8: 7MM, Sources of HLA-B27 Seropositivity Data in Diagnosed AS Cases used in the Epidemiology Forecast
  • Table 9: 7MM, Diagnosed Prevalent Cases of AS, Both Sexes, Ages ≥15 Years, Select Years, N, 2014-2024
  • Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N (Row %), 2014
  • Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages ≥15 Years, N (Row %), 2014
  • Table 12: 7MM, Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, Ages ≥15 Years, Select Years, N, 2014-2024
  • Table 13: 6MM, Prevalent Cases of HLA-B27 Seropositivity in Diagnosed AS Cases, Both Sexes, Ages ≥15 Years, Select Years, N, 2014-2024
  • Table 14: 6MM, HLA-B27 and Non-HLA-B27 Seropositivity Status Among Diagnosed AS Cases, Both Sexes, Ages ≥15 Years, N, 2014
  • Table 15: 7MM, Diagnosed Prevalent Cases of AS, Both Sexes, Ages ≥15 Years, Select Years, N, 2014-2024
  • Table 16: 7MM, Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, Ages ≥15 Years, Select Years, N, 2014-2024

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of AS, Both Sexes, Ages ≥15 Years, N, 2014-2024
  • Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N, 2014
  • Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages ≥15 Years, N, 2014
  • Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of AS, Cases per 100,000 Population, Men and Women, 2014
  • Figure 5: 7MM, Diagnosed Prevalent Cases of Nr-axSpA , Both Sexes, Ages ≥15 Years, N, 2014-2024
  • Figure 6: 6MM, Prevalent Cases of HLA-B27 Seropositivity in Diagnosed AS Cases, Both Sexes, Ages ≥15 Years, N, 2014-2024
  • Figure 7: 6MM, HLA-B27 and Non-HLA-B27 Seropositivity Status Among Diagnosed AS Cases, Both Sexes, Ages ≥15 Years, N, 2014
  • Figure 8: 7MM, Diagnosed Prevalent Cases of AS, Both Sexes, Ages ≥15 Years, N, 2014-2024
  • Figure 9: 7MM, Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, Ages ≥15 Years, N, 2014-2024
Back to Top